scholarly journals PREVALENSI ANEMIA PADA PASIEN GAGAL JANTUNG DI RSUP PROF. DR. R. D. KANDOU MANADO PERIODE 2013

e-CliniC ◽  
2015 ◽  
Vol 3 (1) ◽  
Author(s):  
Aaron Ch. Rambi ◽  
Linda W. A. Rotty ◽  
Agnes L. Panda
Keyword(s):  
Heart Failure ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitor ◽  
Age Groups ◽  
Severe Congestive Heart Failure ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Heart Failure Patients ◽  
Significant Difference ◽  
Prevalence Of Anemia

Abstract: Anemia is common in heart failure patients, especially in patients with old age, female, chronic kidney disease, ACE inhibitors (angiotensin-converting-enzyme inhibitors) users and in patients with severe congestive heart failure. Anemia is an independent prognostic factor for mortality. Anemia is characterized by the value of hemoglobin less than 13 g / dl in men and less than 12 g / dl in women. The purpose of this study was to determine the prevalence of anemia in patients with heart failure. This was a descriptive retrospective study. The samples of this study were 834 medical records of hospitalization and ambulatory patients in RSUP Prof. Dr. R. D. Kandou Manado which had hematology examination results in 2013. The results showed that the prevalence of anemia in heart failure patients was 33.6% and mostly were mild anemia (57%). Although not so significant, the proportion of female patients with anemia were higher (33,57%) than male (33,54%). The over 64 years group has the highest proportion of all age groups. Conclusion: Anemia is common in heart failure patients, especially those aged over 64 years. There was no significant difference between the proportion of women and men who were anemic. Most patients suffered from mild anemia.Keywords: anemia, heart failure, prevalenceAbstrak: Anemia sering ditemukan pada gagal jantung terutama pada pasien yang berusia tua, dengan jenis kelamin perempuan, menderita kelainan ginjal kronik, pengguna ACE inhibitor (angiotensin-converting-enzyme inhibitor) dan pada pasien dengan gagal jantung kongestif yang parah. Anemia merupakan faktor prognostik independen terhadap kematian. Anemia ditandai dengan nilai hemoglobin kurang dari 13 g/dl pada laki-laki dan kurang dari 12 g/dl pada perempuan. Tujuan penelitian ini adalah untuk mengetahui prevalensi anemia pada pasien gagal jantung. Penelitian ini bersifat deskriptif retrospektif. Sampel penelitian ini adalah 834 rekam medis pasien rawat inap dan rawat jalan di RSUP Prof. Dr. R. D. Kandou Manado yang memiliki hasil pemeriksaan hematologi. Hasail penelitian menunjukkan bahwa prevalensi anemia pada pasien gagal jantung adalah 33,6% dan sebagian besar menderita anemia ringan (57%). Walaupun tidak begitu signifikan, proporsi dari pasien perempuan dengan anemia lebih tinggi (33,57%) dibandingkan pria (33,54%). Kelompok umur lebih dari 64 thun memiliki proporsi tertinggi dibadingkan semua kelompok umur. Simpulan: Anemia sering ditemukan pada pasien gagal jantung, terutama yang berusia lebih dari 64 tahun. Tidak ada perbedaan yang signifikan antara proporsi dari peremuan dan laki-laki yang menderita anemia. Kebanyakan pasien menderita anemia ringan.Kata kunci: anemia, gagal jantung, prevalensi

scholarly journals Angiotensin-converting enzyme inhibitors (ACEI) or Angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients

2020 ◽  
Author(s):  
Wenjun Wang ◽  
Xiaohui Zhao ◽  
Wei Wei ◽  
Weiwang Fan ◽  
Kai Gao ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitor ◽  
Angiotensin Receptor Blockers ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Significant Difference ◽  
Group A ◽  
Receptor Blockers ◽  
Group B

Abstract Background: To investigate the effects of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARBs) administration to hypertension patients with the coronavirus disease 2019 (COVID-19) induced pneumonia.Methods: We recorded the recovery status of 67 inpatients with hypertension and COVID-19 induced pneumonia in the Raytheon Mountain Hospital in Wuhan during February 12, 2020 and March 30, 2020. Patients treated with ACEI or ARBs were categorized in group A (n = 22), while patients who were not administered either ACEI or ARBs were categorized into group B (n = 45). We did a comparative analysis of various parameters such as the pneumonia progression, length-of-stay in the hospital, and the level of alanine aminotransferase (ALT), serum creatinine (Cr), and creatine kinase (CK) between the day when these patients were admitted to the hospital and the day when the treatment ended.Results: These 67 hypertension cases counted for 33.17% of the total COVID-19 patients. There was no significant difference in the usage of drug treatment of COVID-19 between groups A and B (p > 0.05). During the treatment, 1 case in group A and 3 cases in group B progressed from mild pneumonia into severe pneumonia. Eventually, all patients were cured and discharged after treatment, and no recurrence of COVID-2019 induced pneumonia occurred after the discharge. The length of stays was shorter in group A as compared with group B, but there was no significant difference (p > 0.05). There was also no significant difference in other general parameters between the patients of the groups A and B on the day of admission to the hospital (p > 0.05). The ALT, CK, and Cr levels did not significantly differ between groups A and B on the day of admission and the day of discharge (p > 0.05). Conclusions: To treat the hypertension patients with COVID-19 caused pneumonia, anti-hypertensive drugs (ACEs and ARBs) may be used according to the relative guidelines. The treatment regimen with these drugs does not need to be altered for the COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document